Phase III study of bevacizumab plus docetaxel compared with placebo plus docetaxel for the first-line treatment of human epidermal growth factor receptor 2-negative metastatic breast cancer
| Main Authors: | , , , , , , , , , , , , , , , |
|---|---|
| Format: | Journal Article |
| Published: |
American Society of Clinical Oncology
2010
|
| Online Access: | http://hdl.handle.net/20.500.11937/6136 |
| _version_ | 1848744989900668928 |
|---|---|
| author | Miles, D. Chan, Arlene Dirix, L. Cortés, J. Pivot, X. Tomczak, P. Delozier, T. Sohn, J. Provencher, L. Puglisi, F. Harbeck, N. Steger, G. Schneeweiss, A. Wardley, A. Chlistalla, A. Romieu, G. |
| author_facet | Miles, D. Chan, Arlene Dirix, L. Cortés, J. Pivot, X. Tomczak, P. Delozier, T. Sohn, J. Provencher, L. Puglisi, F. Harbeck, N. Steger, G. Schneeweiss, A. Wardley, A. Chlistalla, A. Romieu, G. |
| author_sort | Miles, D. |
| building | Curtin Institutional Repository |
| collection | Online Access |
| first_indexed | 2025-11-14T06:10:14Z |
| format | Journal Article |
| id | curtin-20.500.11937-6136 |
| institution | Curtin University Malaysia |
| institution_category | Local University |
| last_indexed | 2025-11-14T06:10:14Z |
| publishDate | 2010 |
| publisher | American Society of Clinical Oncology |
| recordtype | eprints |
| repository_type | Digital Repository |
| spelling | curtin-20.500.11937-61362017-02-28T01:30:23Z Phase III study of bevacizumab plus docetaxel compared with placebo plus docetaxel for the first-line treatment of human epidermal growth factor receptor 2-negative metastatic breast cancer Miles, D. Chan, Arlene Dirix, L. Cortés, J. Pivot, X. Tomczak, P. Delozier, T. Sohn, J. Provencher, L. Puglisi, F. Harbeck, N. Steger, G. Schneeweiss, A. Wardley, A. Chlistalla, A. Romieu, G. 2010 Journal Article http://hdl.handle.net/20.500.11937/6136 American Society of Clinical Oncology restricted |
| spellingShingle | Miles, D. Chan, Arlene Dirix, L. Cortés, J. Pivot, X. Tomczak, P. Delozier, T. Sohn, J. Provencher, L. Puglisi, F. Harbeck, N. Steger, G. Schneeweiss, A. Wardley, A. Chlistalla, A. Romieu, G. Phase III study of bevacizumab plus docetaxel compared with placebo plus docetaxel for the first-line treatment of human epidermal growth factor receptor 2-negative metastatic breast cancer |
| title | Phase III study of bevacizumab plus docetaxel compared with placebo plus docetaxel for the first-line treatment of human epidermal growth factor receptor 2-negative metastatic breast cancer |
| title_full | Phase III study of bevacizumab plus docetaxel compared with placebo plus docetaxel for the first-line treatment of human epidermal growth factor receptor 2-negative metastatic breast cancer |
| title_fullStr | Phase III study of bevacizumab plus docetaxel compared with placebo plus docetaxel for the first-line treatment of human epidermal growth factor receptor 2-negative metastatic breast cancer |
| title_full_unstemmed | Phase III study of bevacizumab plus docetaxel compared with placebo plus docetaxel for the first-line treatment of human epidermal growth factor receptor 2-negative metastatic breast cancer |
| title_short | Phase III study of bevacizumab plus docetaxel compared with placebo plus docetaxel for the first-line treatment of human epidermal growth factor receptor 2-negative metastatic breast cancer |
| title_sort | phase iii study of bevacizumab plus docetaxel compared with placebo plus docetaxel for the first-line treatment of human epidermal growth factor receptor 2-negative metastatic breast cancer |
| url | http://hdl.handle.net/20.500.11937/6136 |